Altogether these studies suggest that both nuclear and cytosolic TG2 contribute importantly to HD pathogenesis and should heighten interest in the development of novel small molecule inhibitors of TG2 to consolidate the advances subsequent to our identification and characterization of the selective TG2 inhibitor, ZDON.
In conclusion, stuttering appears to be associated with a heightened risk for the development of personality disorders.
Previous research has indicated that work stress and trauma exposure may place individuals at heightened risk for the development of depression symptomatology.
Moreover, this issue is especially relevant in patients with sepsis, who appear to be at heightened risk for the development of SH.
However, an increased intake of foods rich in beta-carotene has not been found to pose a heightened risk for the development of lung cancer among current and non-smokers [ 25].
As concern about youth obesity continues to mount, there is increasing consideration of widespread policy changes to support improved nutritional and enhanced physical activity offerings for middle school students - a development period of heightened risk for the development of obesity and consequently an important opportunity for prevention.
Executive Board President Anders Lidén, the Permanent Representative of Sweden to the UN, also led UNICEF's governing body through the adoption of several key resolutions – including increased funding to country programmes and a heightened emphasis on the development of public and private partnerships.
Executive Board President Anders Lidén, the Permanent Representative of Sweden to the UN, also led UNICEF's governing body through the adoption of several key resolutions – including increased funding to country programs and a heightened emphasis on the development of public and private partnerships.
Indeed, it has been argued that poor communication may itself pose a risk to health by heightening anxiety and the development of somatoform disorders [ 4].
Recently, the clinical relevance of the EGFR has been heightened in light of the development of the EGFR tyrosine kinase inhibitors, Getifinib and Erlotinib and EGFR monoclonal antibodies Cetuximab that have been demonstrated to have antitumour activity in solid tumours including non-small cell lung cancer (NSCLC) (Giaccone et al, 2004; Herbst et al, 2004a, 2004b; Lynch et al, 2004b).
